XML 42 R22.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Operations and Comprehensive Loss (Details)
12 Months Ended
Dec. 31, 2023
EUR (€)
€ / shares
shares
Dec. 31, 2023
EUR (€)
$ / shares
shares
Dec. 31, 2022
EUR (€)
€ / shares
shares
Dec. 31, 2022
EUR (€)
$ / shares
shares
Dec. 31, 2021
EUR (€)
€ / shares
shares
Consolidated Statements of Operations and Comprehensive Loss (Details) [Line Items]          
Sales and marketing expense € 4,001,299    
Expense 1,000,000        
Personnel cost 1,900,000        
Research and development expense 41,024,131   37,526,090   35,697,935
General and administrative expenses 12,628,756   14,869,564   11,984,722
Other income 13,219,704   20,159,169   € 54,221
Net financial cost 500,000 € 500,000      
Interest income increased 3,200,000        
Short term marketable securities 3,800,000   600,000    
Foreign exchange 4,300,000        
Gain on foreign exchange     2,400,000    
Loss on foreign exchange 1,800,000        
Other financial amount 77,504,518 € 77,504,518 64,810,135 € 64,810,135  
Allowance for credit loss € 300,000   € 300,000    
Weighted number of common shares outstanding | shares 54,940,137 54,940,137 44,207,873 44,207,873 41,629,974
Loss per share | € / shares € 0.78   € 0.67   € 1.1
Exercise price for options outstanding | € / shares 0.01   0.01    
weighted average fair value of options granted | (per share) € 2.39 € 2.58      
Weighted average fair value options granted | (per share)     € 1.61 € 1.7  
Options granted | shares 1,735,750   1,966,666   1,219,074
Options forfeited | shares 31,000       36,400
Options exercised | shares 105,327   14,930    
Expected dividends | shares        
Research and Development Expense [Member]          
Consolidated Statements of Operations and Comprehensive Loss (Details) [Line Items]          
Research and development expense € 3,500,000        
General and Administrative Expenses [Member]          
Consolidated Statements of Operations and Comprehensive Loss (Details) [Line Items]          
General and administrative expenses € 2,200,000        
2017 [Member]          
Consolidated Statements of Operations and Comprehensive Loss (Details) [Line Items]          
Conversion rate | € / shares € 0.905   € 0.9376    
Average rate | € / shares € 0.9246   € 0.9489    
Weighted average remaining contractual life     2016 years    
Weighted average remaining contractual life 6 years 7 months 9 days   6 years 8 months 12 days    
Maximum number of common shares available for grant | shares 2,341,097        
Ordinary shares percentage 4.00%        
2016 Plan [Member]          
Consolidated Statements of Operations and Comprehensive Loss (Details) [Line Items]          
Weighted average remaining contractual life 7 years 11 months 8 days   8 years 11 months 8 days    
Bottom of Range [Member]          
Consolidated Statements of Operations and Comprehensive Loss (Details) [Line Items]          
Exercise price range | (per share) € 1.74 1.86 € 1.74 1.86  
Top of Range [Member]          
Consolidated Statements of Operations and Comprehensive Loss (Details) [Line Items]          
Exercise price range | (per share) € 4.82 5.14 € 4.82 5.14  
InflaRx GmbH [Member]          
Consolidated Statements of Operations and Comprehensive Loss (Details) [Line Items]          
Conversion rate | $ / shares   0.905   0.9376  
Average rate | $ / shares   € 0.9246   € 0.9489  
Executive Management [Member]          
Consolidated Statements of Operations and Comprehensive Loss (Details) [Line Items]          
Options granted | shares 1,136,000   1,223,500   1,134,436
Options forfeited | shares     136,259    
Credit risk [Member]          
Consolidated Statements of Operations and Comprehensive Loss (Details) [Line Items]          
Other financial amount € 600,000 € 600,000